CorFlow Revenue and Competitors

CorFlow was founded on the belief that current PCI and cardiac care remains suboptimal due the fact that underlying microvascular dysfunction and obstruction is not detected and treated adequately. CorFlow believes, like much of the medical community, that the next frontier of innovation and positive impact on clinical outcomes in cardiology and beyond will come from the microvascular space. \n\nOur first solution is a system that will be the first to diagnose microvascular obstruction (MVO) in real time during PCI and serve as a treatment platform in the cath lab. There are ongoing clinical studies to demonstrate safety and efficacy so the platform remains investigational use only.\n\nOur Mission\n\n- To extend and improve the quality of human life with a relentless pursuit to solve unmet medical needs\n\nOur Vision\n\n- To be the leader in diagnostic and therapeutic solutions for restoring healthy microvascular blood flow anywhere in the human body where a critical need exists\n\nOur Values\n\n- To place quality above all else\n- To treat all people with the highest moral and ethical standards\n- To be a fair partner to everyone we work with and serve\n- To foster inclusion, transparency, well-being and positivity with our employees while chasing ambitious goals\n- To embrace a holistic view of success, inclusive of environmental, social and governance targets we hold ourselves accountable for\n\nCorFlow was founded in 2016 in Baar, Switzerland and now has offices in both Baar and Bern, Switzerland. The company has been financed by a combination of seed funding by angel investors, Venture Capital, and grants via a partnership with the Swiss government that awards significant innovation to improve health care. The Series A financing round closed in 2021, and a Series B round is targeted for 2023.\n\nOur CEO is Paul Mead, who brings close to 20 years of operational experience in medtech working for Medtronic. The Chairman of our Board is Rick Geoffrion, CEO of Cyrano Therapeutics.